

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Vincent Medical Holdings Limited**

**永勝醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock code: 1612)

### **POSITIVE PROFIT ALERT**

This announcement is made by Vincent Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the preliminary review of the Group’s unaudited consolidated management accounts for the six months ended 30 June 2020 (the “**Period**”) and information currently available to the Company, the Group is expected to record an unaudited profit attributable to owners of the Company for the Period of not less than HK\$80.0 million, as compared to that of HK\$13.7 million for the six months ended 30 June 2019.

The surge in profit attributable to owners of the Company for the Period was mainly attributable to the following factors:

- (i) a 105.8% jump in the Group’s total revenue which was primarily attributable to the significant increase in sales of the Group’s respiratory devices and disposables during the COVID-19 pandemic and the growth in demand for the O2FLO respiratory unit and the humidification system under the original brand manufacturing (“**OBM**”) segment; and
- (ii) the increase in operating profit margin primarily attributable to greater economies of scale in production and the increased contribution from the OBM segment which generally generate a relatively higher operating profit margin than the original equipment manufacturing (“**OEM**”) segment.

The segmental revenue information by business segment for the Period is summarised as below:

	<b>For the six months ended 30 June</b>		
	<b>2020</b>	2019	
	<i>HK\$ million</i>	<i>HK\$ million</i>	Change
	<b>(unaudited)</b>	(unaudited)	
OEM	<b>252.4</b>	185.8	+35.8%
OBM	<b>255.0</b>	60.7	+320.1%
Total	<b>507.4</b>	246.5	+105.8%

As at the date of this announcement, the Company is still in the process of finalising the interim results of the Group for the Period. The information contained herein is only based on a preliminary assessment by the management of the Company with reference to the unaudited consolidated management accounts of the Group for the Period and the unaudited information currently available to the Board, which have not been confirmed or reviewed by the audit committee of the Company and have not been audited or reviewed by the Company's auditor. Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for the Period which will be published before the end of August 2020 pursuant to the requirements of the Listing Rules.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Vincent Medical Holdings Limited**  
**Choi Man Shing**  
*Chairman and Executive Director*

Hong Kong, 13 July 2020

*As at the date of this announcement, the Board comprises Mr. Choi Man Shing, Mr. To Ki Cheung, Mr. Koh Ming Fai and Mr. Fu Kwok Fu as executive Directors, Mr. Guo Pengcheng as a non-executive Director, and Mr. Mok Kwok Cheung Rupert, Mr. Au Yu Chiu Steven and Prof. Yung Kai Leung as independent non-executive Directors.*